1. Home
  2. SPRO vs SKYX Comparison

SPRO vs SKYX Comparison

Compare SPRO & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • SKYX
  • Stock Information
  • Founded
  • SPRO 2013
  • SKYX 2004
  • Country
  • SPRO United States
  • SKYX United States
  • Employees
  • SPRO N/A
  • SKYX N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • SKYX Building Products
  • Sector
  • SPRO Health Care
  • SKYX Consumer Discretionary
  • Exchange
  • SPRO Nasdaq
  • SKYX Nasdaq
  • Market Cap
  • SPRO 128.9M
  • SKYX 139.3M
  • IPO Year
  • SPRO 2017
  • SKYX 2022
  • Fundamental
  • Price
  • SPRO $2.36
  • SKYX $1.68
  • Analyst Decision
  • SPRO Buy
  • SKYX Strong Buy
  • Analyst Count
  • SPRO 4
  • SKYX 1
  • Target Price
  • SPRO $5.00
  • SKYX $5.00
  • AVG Volume (30 Days)
  • SPRO 1.2M
  • SKYX 908.5K
  • Earning Date
  • SPRO 11-13-2025
  • SKYX 11-10-2025
  • Dividend Yield
  • SPRO N/A
  • SKYX N/A
  • EPS Growth
  • SPRO N/A
  • SKYX N/A
  • EPS
  • SPRO N/A
  • SKYX N/A
  • Revenue
  • SPRO $48,576,000.00
  • SKYX $89,028,500.00
  • Revenue This Year
  • SPRO N/A
  • SKYX $8.81
  • Revenue Next Year
  • SPRO N/A
  • SKYX $28.17
  • P/E Ratio
  • SPRO N/A
  • SKYX N/A
  • Revenue Growth
  • SPRO N/A
  • SKYX 5.71
  • 52 Week Low
  • SPRO $0.51
  • SKYX $0.88
  • 52 Week High
  • SPRO $3.22
  • SKYX $2.14
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 57.47
  • SKYX 61.51
  • Support Level
  • SPRO $2.16
  • SKYX $1.52
  • Resistance Level
  • SPRO $2.44
  • SKYX $1.88
  • Average True Range (ATR)
  • SPRO 0.12
  • SKYX 0.16
  • MACD
  • SPRO -0.00
  • SKYX 0.03
  • Stochastic Oscillator
  • SPRO 55.24
  • SKYX 67.69

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SKYX SKYX Platforms Corp.

SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.

Share on Social Networks: